Salk inactivated poliovirus vaccine + bivalent oral poliovirus vaccine

This sequential immunization regimen, developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS), is designed for the prevention of poliomyelitis in infants. The regimen combines the Salk-strain inactivated poliovirus vaccine (cIPV) with a bivalent oral poliovirus vaccine (bOPV) targeting poliovirus types 1 and 3. The strategy typically involves an initial intramuscular dose of cIPV to establish systemic immunity against all three poliovirus serotypes (1, 2, and 3) without the risk of vaccine-associated paralytic polio (VAPP), followed by oral doses of bOPV to enhance mucosal immunity against types 1 and 3. This approach aligns with the World Health Organization's Global Polio Eradication Initiative strategy to phase out trivalent oral vaccines and mitigate the risk of vaccine-derived polioviruses.

Other names

cIPV + bOPVSalk IPV + bOPVIPV-bOPV sequential immunization schedule